{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T04:05:51Z","timestamp":1783829151419,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81361138021"],"award-info":[{"award-number":["81361138021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2017.00246","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T03:48:48Z","timestamp":1497584928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["In vitro Pharmacokinetics\/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae"],"prefix":"10.3389","volume":"7","author":[{"given":"Wei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinru","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshui","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ijantimicag.2015.07.019","article-title":"The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic\/pharmacodynamic model experiments","volume":"46","author":"Albur","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ijantimicag.2011.11.012","article-title":"Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin","volume":"39","author":"Apisarnthanarak","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B3","volume-title":"Antibiotic Resistance Threats in the United States, 2013","year":"2013"},{"key":"B4","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing. 26th Informational Supplement","year":"2016"},{"key":"B5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/27.suppl_C.29","article-title":"Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections","volume":"27","author":"Craig","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/Pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"B7","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1128\/AAC.41.6.1281","article-title":"Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model","volume":"41","author":"Firsov","year":"1997","journal-title":"Antimicrob. Agents Chemother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1128\/AAC.34.4.614","article-title":"Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity","volume":"34","author":"Garraffo","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3109\/00365548.2012.747694","article-title":"Rational use of aminoglycosides: review and recommendations by the Swedish Reference Group for Antibiotics (SRGA)","volume":"45","author":"Hanberger","year":"2013","journal-title":"Scand. J. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae, carbapenem-resistant enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"B11","article-title":"A novel mechanism of action for the synergistic antibacterial activity of colistin and fosfomycin","volume-title":"Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/International Congress of Chemotherapy and Infection (ICC) Annual Meeting, San Diego, CA., 2015. Slide session 150 (C)","author":"Lahiri","year":"2015"},{"key":"B12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF00544588","article-title":"Influence of the route of administration on the pharmacokinetics of amikacin","volume":"19","author":"Lanao","year":"1981","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/jac\/dkn469","article-title":"Aminoglycoside drugs in clinical practice: an evidence-based approach","volume":"63","author":"Leibovici","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.clinthera.2008.01.015","article-title":"Colistin serum concentrations after intravenous administration in critically Ill Patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study","volume":"30","author":"Markou","year":"2008","journal-title":"Clin. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1517\/17425255.2011.541439","article-title":"Pharmacokinetic evaluation of colistin sodium. Expert opinion on drug metabolism & toxicology","volume":"7","author":"Michalopoulos","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1185\/03007995.2011.626557","article-title":"Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects","volume":"27","author":"Mizuyachi","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"B17","unstructured":"Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated 292 Patients With Gram-Negative and\/or Gram-Positive Bacterial Colonization. 293 ClinicalTrials.gov Identifier: NCT022183592016"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1086\/592412","article-title":"Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies","volume":"29","author":"Patel","year":"2008","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/QCO.0000000000000109","article-title":"Options for treating carbapenem-resistant Enterobacteriaceae","volume":"27","author":"Rafailidis","year":"2014","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1128\/AAC.49.11.4448-4454.2005","article-title":"Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles","volume":"49","author":"Sauermann","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e01763","DOI":"10.1128\/AAC.01763-16","article-title":"Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: experimental basis for combination therapy","volume":"61","author":"Sime","year":"2016","journal-title":"Antimicrob. Agents Chemother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fcimb.2017.00246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T04:58:48Z","timestamp":1569473928000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fcimb.2017.00246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,16]]},"references-count":22,"alternative-id":["10.3389\/fcimb.2017.00246"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2017.00246","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,16]]},"article-number":"246"}}